3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
6
Rectal Neoplasms
1
Prostatic Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastric Cancer After D2 Lymph Node Dissection
1
Gallbladder Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Anastomotic Leak
1
Interventions
lutetium Lu 177 dotatate
5
copper dotatate CU-64
3
Magnetic Resonance Spectroscopy
3
lanreotide
2
gallium Ga 68 dotatate
2
Nivolumab
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Carboplatin
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
pasireotide
1
irinotecan sucrosofate
1
folfirinox
1
cabozantinib
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Somatostatin
1
Resveratrol
1
Radiosurgery
1
Octreotide
1
Ipilimumab
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastro-enteropancreatic neuroendocrine tumor
×
Somatostatin
×
Clear all
NCT05701241
2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4
Recruiting
270 enrolled